Hemideina has raised funds via a private placement
Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.
Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.
Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.
Elizabeth Williams
CEO and co-founder, Hemideina
Falar com a equipa da transação
Transações relacionadas
Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Saber maisDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Saber maisXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Saber mais